Current Report Filing (8-k)
December 02 2022 - 06:06AM
Edgar (US Regulatory)
0001676163
false
0001676163
2022-12-01
2022-12-01
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
Pursuant to Section
13 or 15(d) of The Securities Exchange Act of 1934
Date of report (Date
of earliest event reported): December 1, 2022
AVRA MEDICAL ROBOTICS,
INC.
(Exact name of registrant
as specified in its charter)
Florida |
|
333-216054 |
|
47-3478854 |
(State or
Other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
3259 Progress
Drive
Orlando, Florida |
|
32826 |
(Address of
Principal Executive Offices) |
|
(Zip Code) |
Registrant’s telephone
number, including area code: (407) 956-2250
(Former name or former
address, if changed since last report)
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
☐ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered
pursuant to Section 12(b) of the Act:
Title
of each Class |
|
Trading
Symbol |
|
Name
of each exchange on which registered |
None |
|
N/A |
|
N/A |
Indicate by check mark
whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☒
If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
As used in this Current
Report on Form 8-K (this “Report”), and unless otherwise indicated, the terms “AVRA,” “the
Company,” “we,” “us” and “our” refer to Avra Medical Robotics, Inc.
Item 8.01 Other Information.
On December 1, 2022,
AVRA issued a press release announcing that as of November 30, 2022, it had filed all required periodic reports with the Securities and
Exchange Commission and accordingly was current in its filing SEC status.
A copy of the press
release is filed herewith as Exhibit 99.1.
Item 9.01 Financial
Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Dated: December 2, 2022 |
AVRA MEDICAL ROBOTICS,
INC. |
|
|
|
By: |
/s/
Barry F. Cohen |
|
|
Barry F. Cohen, Chief Executive Officer |
AVRA Medical Robotics (PK) (USOTC:AVMR)
Historical Stock Chart
From Feb 2024 to Mar 2024
AVRA Medical Robotics (PK) (USOTC:AVMR)
Historical Stock Chart
From Mar 2023 to Mar 2024